2024 Meeting Materials, Oncologic Drugs Advisory Committee
This page contains the meeting materials for the Oncologic Drugs Advisory Committee meetings for 2024.
This page contains the meeting materials for the Oncologic Drugs Advisory Committee meetings for 2024.
Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been recently approved by FDA, driven by basket trials that have demonstrated their efficacy and…
PURPOSE Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known…
PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of…
Purpose Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two…
One to two percent of non–small-cell lung cancers (NSCLCs) harbor ROS1 gene rearrangements. 1 – 3 ROS1 gene rearrangement leads to constitutive activation receptor tyrosine…
Solid pseudopapillary neoplasms (SPNs) of the pancreas are exocrine neoplasms that predominantly affect young females and are considered to have low malignant potential. Surgical resection…
Financial support: Jie Wu, Jie Wu Administrative support: Vivek Subbiah, Vivek Subbiah Provision of study materials or patients: Sireesha Yedururi, Vivek Subbiah, Sireesha Yedururi, Vivek…
Medullary thyroid cancer (MTC) is a neuroendocrine tumor that originates from the parafollicular cells (or C cells) of the thyroid gland and account s for…
(Bloomberg) — When Oracle Corp. spent $28 billion two years ago to acquire electronic-records company Cerner Corp., it promised a revolution in health care technology.…